Jay Kranzler Biography and Net Worth

Director of Avenue Therapeutics

Dr. Kranzler joined our Board of Directors in February 2017 and became Chairman in March 2023. Dr. Kranzler has been a Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. He is currently acting as Chief Executive Officer of Regenovation, a regenerative medicine company, and is a Board Member of Methylation Sciences, Pastorus, and ImmunoBrain Checkpoint, all companies focused on developing therapeutics for psychiatric or neurological disorders. Dr. Kranzler started his career at McKinsey & Company where he established the Firm’s pharmaceutical practice. He served as Chief Executive Officer (CEO) of Cytel Corporation, a company focused on the development of immunomodulatory drugs. Following Cytel, Dr. Kranzler became the CEO of Cypress Bioscience, where he was credited for the development of Savella™ (milnacipran) for the treatment of fibromyalgia. Dr. Kranzler was also Vice President, Head of External R&D Innovation and Worldwide R&D Strategic Investments at Pfizer. During his career, Dr. Kranzler has developed drugs, medical devices, as well as diagnostics, and is the inventor on over 30 patents. Dr. Kranzler graduated from Yale University School of Medicine with MD and PhD degrees with a focus in psychopharmacology.

What is Jay D. Kranzler's net worth?: The estimated net worth of Jay D. Kranzler is at least $223.88 as of November 5th, 2024. Dr. Kranzler owns 559 shares of Avenue Therapeutics stock worth more than $224 as of October 12th. This net worth evaluation does not reflect any other assets that Dr. Kranzler may own. Learn More about Jay D. Kranzler's net worth.
How do I contact Jay D. Kranzler?: The corporate mailing address for Dr. Kranzler and other Avenue Therapeutics executives is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. Avenue Therapeutics can also be reached via phone at (781) 652-4500 and via email at [email protected]. Learn More on Jay D. Kranzler's contact information.
Has Jay D. Kranzler been buying or selling shares of Avenue Therapeutics?: Jay D. Kranzler has not been actively trading shares of Avenue Therapeutics during the past quarter. Most recently, Jay D. Kranzler sold 61 shares of the business's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $2.24, for a transaction totalling $136.64. Following the completion of the sale, the director now directly owns 559 shares of the company's stock, valued at $1,252.16. Learn More on Jay D. Kranzler's trading history.
Who are Avenue Therapeutics' active insiders?: Avenue Therapeutics' insider roster includes Neil Herskowitz (Director), Jay Kranzler (Director), and Joseph Vazzano (CFO). Learn More on Avenue Therapeutics' active insiders.

Jay D. Kranzler Insider Trading History at Avenue Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/5/2024	Sell	61	$2.24	$136.64	559

Jay D. Kranzler Buying and Selling Activity at Avenue Therapeutics

Avenue Therapeutics Company Overview

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Today's Range

Now: $0.40

$0.40

$0.45

50 Day Range

MA: $0.43

$0.26

$0.82

2 Week Range

Now: $0.40

$0.15

$0.97

Volume

488 shs

Average Volume

6,798 shs

Market Capitalization

$1.32 million

P/E Ratio

0.02

Dividend Yield

N/A

Beta